Navigation Links
Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Date:5/28/2008

ProLindac Demonstrates Sustained and Significant Reductions in Cancer

Market CA-125

DALLAS, May 28 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that the company gave an invited oral presentation on its lead anticancer compound, ProLindac(TM) at the International Symposium on Polymer Therapeutics: Laboratory to Clinical Practice, taking place from May 26-28 in Valencia, Spain. The presentation was entitled "Promising Safety and Efficacy Results from an Ongoing Clinical Study of ProLindac in Recurrent Ovarian Cancer." ProLindac is Access' novel DACH platinum-polymer prodrug, which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials.

The invited presentation was given by Professor Esteban Cvitkovic, M.D., Access Pharmaceuticals' Senior Director, Clinical Oncology R&D. Professor Cvitkovic presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.

"We continue to be impressed by clinical results that indicate a significant DACH platinum drug effect with a very benign side effect profile," stated Jeffrey B. Davis, Access' President & CEO. "The sustained efficacy and minimal toxicity seen over multiple dosings provides further evidence that ProLindac has the potential to become a very important anticancer agent in the future. We are finalizing our plans for Phase 2 combination trials where we intend to look at multiple solid tumor types with ProLindac in combination with other cancer agents, like taxol and gemcitabine."


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
2. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
10. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014   RapidForce , ... announced today a strategic partnership with professional tennis player ... tennis player, Isner wears RapidForce during competitions to help ... competes this week at the 2014 US Open Tennis ... tape, RapidForce Physio Hybrid Shapes are a revolutionary hybrid ...
(Date:8/28/2014)... 28. August 2014 Sequent ... der Patientenrekrutierung für eine IDE-Pivot-Studie („IDE" ... Beurteilung der Sicherheit und Wirksamkeit des ... („WEB") bekanntgegeben. Adam Arthur, MD, Dozent an ... Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der WEB-IT-Studie, ...
(Date:8/28/2014)... ALISO VIEJO , Californie, 28 ... Inc. a annoncé aujourd,hui le début ... cadre d,une étude  d,exemption des dispositifs ... anglais) destinée à évaluer l,innocuité et ... anévrismes (« WEB »). Le docteur Adam ...
Breaking Medicine Technology:America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 2America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 3America's top-ranked tennis player John Isner Joins Forces with RAPIDFORCE Physio Hybrid Shapes 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
... (Nasdaq: PRGO ; TASE) today announced that it ... foam brought by Stiefel Research Australia Pty. Ltd., a GSK ... in the U. S., a generic version of Men,s Rogaine® ... Rogaine® (Minoxidil) Foam is used to regrow ...
... Informex , the leading meeting place for buyers ... applications, today announced details of its second Latin American Green ... The event will be held in September 2011, with further ... 2011 event follows the success of the inaugural Informex Latin ...
Cached Medicine Technology:Perrigo Announces Settlement of Rogaine® Foam Patent Litigation 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 2Second Annual Latin America 'Green Exchange Conference' Hosted by Informex Focuses on a Sustainable Future for Chemistry 3
(Date:8/28/2014)... UT (PRWEB) August 28, 2014 CMMI (Center ... coordination and integration of care to address patient needs. What ... quality of care outcomes (with more provider accountability) and reduce ... all the people involved in the care of a patient ... figure out how to distribute it. If it sounds complicated, ...
(Date:8/28/2014)... August 28, 2014 GreenRushReview.com, a ... recently launched a “Video” section located at ... information on various cannabis companies in video format. ... an assortment of news clips, interviews, and other ... A portion of the videos can also be ...
(Date:8/28/2014)... August 28, 2014 Genetic testing ... throughout the world, with large reference laboratories as ... laboratories differ with regard to the genetic variants ... payers may struggle to find the most appropriate ... help clients sort through these differences, Hayes, Inc. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 On September ... interview Stephen Isaacs, the chairperson, president and CEO of ... Meet the Mesothelioma Experts live broadcast. The ... director and mesothelioma expert nurse practitioner, Mary Hesdorffer, ... will be Aduro BioTech’s experimental therapy for malignant pleural ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... by alerting women to the link between obesity and ... of endometrial cancer. , Endometrial cancer is the ... cancer. More than 52,600 will learn of a diagnosis ... with weight management challenges to know the early warning ...
Breaking Medicine News(10 mins):Health News:Med-Certification.com Expects Industry "Hiccups" with New Models for Patient Care and Reimbursement 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2
... A study published in the October 15 issue ... the Cleveland Adolescent Sleepiness Questionnaire (CASQ), a new self-completed ... The study, led by James C. Spilsbury, PhD, of ... Ohio, focused on a subsample of 411 adolescents between ...
... 11:30 am EDT, TEL AVIV, Israel, October 15 ... that it has signed,an agreement to acquire 100% of ... Blessing Biotech GmbH (together the "Gewurzmuller,Group"), in consideration for ... The Company will be hosting a conference call ...
... Island Hospital and Brown University researchers reported that 18 percent ... initial psychiatric clearance for the surgery. The study is the ... for surgery, and the largest to determine the percentage of ... exclusion. It was published in the October edition of the ...
... of ills such as heart disease , , SUNDAY, ... collections of genetic and clinical data available free to ... Institutes of Health. , The Web-based SHARe (SNP Health ... from a number of large population-based studies, starting with ...
... breathing disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay ... airway pressure (CPAP) to treat people with obstructive sleep ... of the arteries -- within months, a new study ... of a direct link between obstructive sleep apnea and ...
... BEACH, Calif., Oct. 12 History,will be written if ... Act during a vote scheduled for next week. It ... law regarding swimming pool and spa safety.,The National Drowning ... but with wording similar to HR 1721 passed on ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007 2Health News:1 in 5 bariatric surgery candidates not psychologically cleared for surgery 2Health News:U.S. Unveils Database of Genetic, Clinical Research 2Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:NDPA Urges Passage of Historic Pool Bill 2
... the semi-quantitative determination of specific IgA autoantibodies ... of the anti-Gliadin IgA assay can be ... of diseases associated with elevated levels of ... these autoantibodies are one indicator in a ...
... ADVIA Urinalysis WorkCell System - A ... tests per hour, with true load-and-go ... of Clinitek Atlas and UF-100 for ... regarded systems working together deliver utmost ...
... (EIA) test kit is to be used ... in human serum during the second half ... (unconjugated) procedure is an enzyme immunoassay which ... binding. In the procedure, estriol is ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
Medicine Products: